The status could support staged transitions to new manufacturing processes, potentially mitigating some risks of high-stakes ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN ...

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell leukemia.

Over the last decade, the number of cell and gene therapy clinical trials has more than tripled. In this article, several ...

Motixafortide alone and in combination with natalizumab can support the collection of the large number of stem cells required ...

Operational real-world data analyzed from patients prescribed ZYNTEGLO™ and LYFGENIA™Data demonstrates the value proposition of one-time, durable gene therapy for the treatment of sickle cell disease ...

In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met ...

The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

The National Organization for Rare Disorders (NORD®) has designated UC Davis Health as a NORD Rare Disease Center of ...

Bispecific antibodies bring multiple tumor-cell-killing mechanisms into play simultaneously. When a T cell is activated and ...

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...